BioCentury
ARTICLE | Clinical News

SARcode reports Phase III data for dry eye treatment

October 24, 2012 1:20 AM UTC

SARcode Bioscience Inc. (Brisbane, Calif.) said twice-daily lifitegrast met the co-primary endpoint of improving inferior corneal staining scores from baseline to week 12 vs. placebo in the Phase III OPUS-1 trial to treat dry eye disease (p=0.0007). Lifitegrast missed the co-primary endpoint of improving visual-related function score as measured by Ocular Surface Disease Index (OSDI) score vs. placebo (p=0.7894). On secondary endpoints, lifitegrast significantly improved total corneal staining (p=0.0148), mean ocular discomfort (p=0.0273) and mean eye dryness scores (p=0.0291) from baseline to week 12 vs. placebo. The product is an eye drop formulation of a small molecule LFA-1 antagonist. ...